Anterior Uveitis Treatment Market Size, Share, Growth Analysis, By Treatment(Corticosteroids, Cycloplegic Agents), By Distribution Channel(Hospital, Retail) - Industry Forecast 2024-2031

Global Anterior Uveitis Treatment Market size was valued at USD 350 million in 2022 and is poised to grow from USD 371 billion in 2023 to USD 591.32 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The surge in cases of anterior uveitis is a pivotal factor propelling its expansion. This condition triggers inflammation in the front portion of the uvea in the eye. Managing this vision-endangering ailment predominantly involves employing corticosteroids and immunosuppressive agents. Typically, corticosteroid eye drops are recommended in a majority of instances. Additionally, anterior uveitis can emerge as a consequence of diverse underlying conditions, further amplifying its prevalence.

The prescription of corticosteroids, as noted by the United Kingdom's National Health Service, hinges on the specific type of uveitis, as these medications disrupt the immune system's normal functioning. In 2021, 12.7% of the global population was aged 60 or above, with projections indicating a rise in the coming years. The vulnerability to this ailment escalates with advancing age.

Innovations in product applications and treatment approaches are continuously advancing. A notable milestone was the approval of Humira for uveitis treatment, signifying a significant breakthrough. Thus, factors like the expanding elderly population, the upsurge in disease occurrences, and novel product innovations are expected to steer growth. Indicators of anterior uveitis may encompass eye redness, vision blurring, reduced pupil size, and light sensitivity. Left untreated, these symptoms can lead to irreversible blindness.

The mounting frequency of ocular infections, coupled with heightened awareness about diverse treatment methods, is anticipated to bolster market expansion throughout the projected period. Sizeable healthcare expenditures, rising disposable incomes, and favorable governmental regulations are among other catalysts driving the market. Anterior uveitis stands as a prevalent form of ocular inflammation frequently reported to primary eye care practitioners.

Individuals afflicted with anterior uveitis could experience altered Intraocular Pressure (IOP), leading to blood accumulation in the front chamber and impairing visual clarity. Treatment involving corticosteroids may result in elevated IOP, constituting an unfavorable drug reaction. Notable complications linked with this eye ailment encompass glaucoma, cataracts, cystoid macular edema, and band keratopathy.

US Anterior Uveitis Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.